European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreThe committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreKeurig Dr Pepper's second-quarter earnings and revenue met Wall Street's expectations. Source link
Read MoreTesla shares fell more than 8% in pre-market trade in the U.S. after it reported second-quarter earnings that missed expectations.
Read MoreThese stocks have shown an ability to continue growing revenue at a strong rate. Source link
Read MoreThe electric vehicle maker posted better-than-expected second-quarter delivery numbers, but delay in its Robotaxi drove shares lower in July. Source
Read MoreGM is again slowing its plans for all-electric vehicles by further delaying a second electric U.S. truck plant and the
Read MoreThe U.S. election just '"got way more interesting," a senior EU diplomat told CNBC Monday. Source link
Read MoreLater Tuesday, India is slated to unveil its first budget under Prime Minister Narendra Modi's third five-year term. Source link
Read MoreTema ETFs' Yuri Khodjamirian described one of the stocks as an "under the radar" play. Source link
Read More